Skip to main content
Have a personal or library account? Click to login
Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème Cover

Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème

Radiology and Oncology
Volume 42 (2008): Issue 4 (December 2008)
By:  and    
Open Access
|Dec 2008
References

References

  1. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy.2002;2-8.
    Open DOISearch in Google Scholar
  2. Moosmann N, Heinemann V. Cetuximab in the treatment of metastatic colorectal cancer.2007;243-56.
    Open DOISearch in Google Scholar
  3. Frieze DA, McCune JS. Current status of cetuximab for the treatment of patients with solid tumors.2006;241-50.
    Open DOISearch in Google Scholar
  4. Summary of product characteristics.
    Search in Google Scholar
  5. Smrdel U, Kovač V. Erlotinib in previously treated non-small-cell lung cancer.2006;39-42.
    Search in Google Scholar
  6. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody.2005;107-127.
    Open DOISearch in Google Scholar
  7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.2004;337-45.
    Open DOISearch in Google Scholar
  8. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.2008;5335-43.
    Open DOISearch in Google Scholar
  9. Scheiuthauer W, Sobrero A, Lenz HJ, Maurel J, Lutz M, Middleton G., et al. Cetuximab plus irinotecan in patients with mCRC who failed prior oxaliplatin-based therapy: the EPIC trial. [Abstract].2007;235
    Search in Google Scholar
  10. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Schepotin I, Maurel J., et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. ASCO 2007.2007;Abstract 4000.
    Open DOISearch in Google Scholar
  11. Bokemeyer C, Staroslawska E, Makhson A, Bondarenko I, Hartmann JT, Shelygin Y, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): a large-scale phase II study, OPUS. [Abstract].2007;236
    Open DOISearch in Google Scholar
  12. Salz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM., et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer. The BOND-2 study.2007;4516-8.
    Search in Google Scholar
  13. Adam R, Aloia T, Levi F, de Haas RJ, Paule B, Bralet MP., et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic treatment.2007;4593-602.
    Open DOISearch in Google Scholar
  14. Ciardiello F, Cervantes A, Vega-Villegas ME, Casado E, Rodriguez-Braun E, Martinelli E., et al. Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics(PK) and pharmacodynamics (PD) study of weekly (q1w) add q2w schedules. [Abstract].2007;247
    Open DOISearch in Google Scholar
  15. Pfeiffer P, Bjerregaard JK, Qvortrup C, Jensen BV, Yilmaz M, Nielsen D. Simplification of cetuximab (Cet) administration: double dose of every second week as a 60 minute infusion.2007;Abstract 4133.
    Open DOISearch in Google Scholar
  16. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.2006;567-78.
    Open DOISearch in Google Scholar
  17. Burtness B, Goldwasser MA, Flood W, Mattar B, Forrastiere AA. Phase III randomized trial of cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern Cooperative Oncology Group study.2005;8646-54.
    Open DOISearch in Google Scholar
  18. Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C., et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.2006;2866-72.
    Open DOISearch in Google Scholar
  19. Bernier J. Cetuximab in the treatment of head and neck cancer.2006;1539-52.
    Open DOISearch in Google Scholar
  20. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.2004;1201-8.
    Open DOISearch in Google Scholar
  21. Carson EJ, Novak AM, Stella PJ. Hypomagnesemia in patients with stage IV colorectal cancer treated with cetuximab as a single agent. [Abstract 3655].2005;248-54.
    Search in Google Scholar
  22. Vallbohmer D, Lenz HJ. Epidermal growth factor receptor as a target for chemotherapy.2005;S19-27.
    Open DOISearch in Google Scholar
  23. Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?2004;479-88.
    Search in Google Scholar
  24. Perez- Soler R, Zou Y, Li T, Tornos C, Ling Y. Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin.2006;Abstract 3036.
    Open DOISearch in Google Scholar
  25. National Cancer Institute. Common terminology criteria for adverse events v. 3.0
    Search in Google Scholar
  26. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the epidermal growth factor receptor antibody C225.2001;1169-76.
    Open DOISearch in Google Scholar
  27. Segaert1 S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors2005;1425-33.
    Open DOISearch in Google Scholar
  28. Agero ALC, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatological side-effects associated with the epidermal growth factor receptor inhibitors.2006;657-70.
    Open DOISearch in Google Scholar
  29. Galimont-Collen AFS, Vos LE, Lavrijsen APM, Ouwrkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.2007;845-51.
    Open DOISearch in Google Scholar
  30. Velenik V, Oblak I, Anderluh F. Quality of life in patients after combined modality treatment of rectal cancer: Report of a prospective phase II study.2008:207-14.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/v10019-008-0022-4 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 215 - 224
Published on: Dec 29, 2008
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
cetuximab,
cutaneous side-effects,
vitamin K1 crème,
colorectal cancer
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2008 Janja Ocvirk, Martina Rebersek, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 42 (2008): Issue 4 (December 2008)
Previous article
Next article